Table 1 Demographics and clinical pathological features of LiqBreasTrack-enrolled patients
Characteristics | N (%) |
|---|---|
Age, years (range) | 56.8 (39.4–83.5) |
ECOG Performance Status ≤2 | 22 (100) |
IHC molecular markers | |
Primary tumor tissues | 22 |
ER+ and/or PgR+ | 15 (68.2) |
ER- and/or PgR- | 7 (31.8) |
HER2 1+/SISH or FISH+ | 3 (13.6) |
HER2 2+/SISH or FISH+ | 2 (9.1) |
HER2 3+ | 17 (77.3) |
Metastatic tumor tissues | 9 |
ER+ and/or PgR+ | 6 (66.7) |
ER- and/or PgR- | 3 (33.3) |
HER2 1+/SISH or FISH+ | 1 (11.1) |
HER2 2+/SISH or FISH+ | 3 (33.3) |
HER2 3+ | 5 (55.6) |
Previous lines of therapy | |
1 | 14 (63.6) |
2 | 7 (31.8) |
3 | 1 (4.5) |
Pertuzumab as first line treatment | |
Yes | 9 (40.9) |
No | 13 (59.1) |
Dominant Metastatic sites | |
Liver | 3 (13.6) |
Lung | 3 (13.6) |
Bone | 5 (22.7) |
Soft tissues | 7 (31.9) |
Brain | 4 (18.2) |
Number of metastatic sites per patient | |
1 | 8 (36.6) |
2 | 9 (40.9) |
≥ 3 | 5 (22.7) |